« Back
Home /
EPZ-719

EPZ-719

Item no.	HY-139626-5mg
Manufacturer	MedChem Express
CASRN	2697176-16-0
Amount	5 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 1 mg 25 mg 50 mg 5 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Molecules
Specific against	other
Purity	99.85
Citations	[1]Lampe JW, et al. Discovery of a First-in-Class Inhibitor of the Histone Methyltransferase SETD2 Suitable for Preclinical Studies. ACS Med Chem Lett. 2021 Aug 24;12(10):1539-1545.
Smiles	CC1=C2C(C=C(C(N[C@@H]3CCC[C@H](N4C[C@@H](N(S(=O)(C)=O)C)CC4)C3)=O)N2)=C(F)C=C1
ECLASS 10.1	32169090
ECLASS 11.0	32169090
UNSPSC	12000000
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Targets	Histone Methyltransferase
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	450.57
Product Description	EPZ-719 is a selective, orally effective SETD2 inhibitor with an IC50 value of 0.005 μM. EPZ-719 has anticancer activity[1].
Manufacturer - Research Area	Cancer
Solubility	DMSO: 50 mg/mL (ultrasonic)
Manufacturer - Pathway	Epigenetics
Isoform	SETD2/KMT3A
Clinical information	No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-139626-5mg-safety-datasheet.pdf